{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T03:37:56Z","timestamp":1752550676312,"version":"3.41.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06205-x","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T11:18:18Z","timestamp":1747912698000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of the R2-MTX regimen in primary central nervous system lymphoma (PCNSL): a single-center retrospective analysis"],"prefix":"10.1007","volume":"151","author":[{"given":"Lijie","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"6205_CR1","doi-asserted-by":"publisher","unstructured":"Abrey LE, Batchelor TT, Ferreri AJ et al (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034\u20135043. https:\/\/doi.org\/10.1200\/jco.2005.13.524","DOI":"10.1200\/jco.2005.13.524"},{"key":"6205_CR2","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1200\/jco.2006.08.2941","volume":"24","author":"LE Abrey","year":"2006","unstructured":"Abrey LE, Ben-Porat L, Panageas KS et al (2006) Primary central nervous system lymphoma: the memorial Sloan-Kettering Cancer center prognostic model. J Clin Oncol 24:5711\u20135715. https:\/\/doi.org\/10.1200\/jco.2006.08.2941","journal-title":"J Clin Oncol"},{"key":"6205_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.5045\/br.2017.52.4.285","volume":"52","author":"Y Ahn","year":"2017","unstructured":"Ahn Y, Ahn HJ, Yoon DH et al (2017) Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology. Blood Res 52:285\u2013292. https:\/\/doi.org\/10.5045\/br.2017.52.4.285","journal-title":"Blood Res"},{"key":"6205_CR4","doi-asserted-by":"publisher","first-page":"106552","DOI":"10.1016\/j.leukres.2021.106552","volume":"104","author":"S Bettelli","year":"2021","unstructured":"Bettelli S, Marcheselli R, Pozzi S et al (2021) Cell of origin (COO), BCL2\/MYC status and IPI define a group of patients with diffuse large B-cell lymphoma (DLBCL) with poor prognosis in a real-world clinical setting. Leuk Res 104:106552. https:\/\/doi.org\/10.1016\/j.leukres.2021.106552","journal-title":"Leuk Res"},{"key":"6205_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","volume":"20","author":"JE Bromberg","year":"2019","unstructured":"Bromberg JE, Issa S, Bakunina K et al (2019) Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 20:216\u2013228","journal-title":"Lancet Oncol"},{"key":"6205_CR6","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/ajcp\/110.5.607","volume":"110","author":"S Camilleri-Bro\u00ebt","year":"1998","unstructured":"Camilleri-Bro\u00ebt S, Martin A, Moreau A et al (1998) Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest est d\u2019\u00e9tude des leuc\u00e9nies et autres maladies du sang (GOELAMS). Am J Clin Pathol 110:607\u2013612. https:\/\/doi.org\/10.1093\/ajcp\/110.5.607","journal-title":"Am J Clin Pathol"},{"key":"6205_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1182\/blood-2005-03-1024","volume":"107","author":"S Camilleri-Bro\u00ebt","year":"2006","unstructured":"Camilleri-Bro\u00ebt S, Crini\u00e8re E, Bro\u00ebt P et al (2006) A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107:190\u2013196. https:\/\/doi.org\/10.1182\/blood-2005-03-1024","journal-title":"Blood"},{"key":"6205_CR8","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:5019\u20135032. https:\/\/doi.org\/10.1182\/blood-2011-01-293050","journal-title":"Blood"},{"key":"6205_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/ng.2007.30","volume":"40","author":"TC Chang","year":"2008","unstructured":"Chang TC, Yu D, Lee YS et al (2008) Widespread MicroRNA repression by Myc contributes to tumorigenesis. Nat Genet 40:43\u201350. https:\/\/doi.org\/10.1038\/ng.2007.30","journal-title":"Nat Genet"},{"key":"6205_CR10","doi-asserted-by":"publisher","first-page":"8676","DOI":"10.1002\/cam4.3499","volume":"9","author":"F Chen","year":"2020","unstructured":"Chen F, Pang D, Guo H et al (2020) Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use. Cancer Med 9:8676\u20138684. https:\/\/doi.org\/10.1002\/cam4.3499","journal-title":"Cancer Med"},{"key":"6205_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s11060-016-2318-3","volume":"131","author":"A Darlix","year":"2017","unstructured":"Darlix A, Zouaoui S, Rigau V et al (2017) Epidemiology for primary brain tumors: a nationwide population-based study. J Neurooncol 131:525\u2013546. https:\/\/doi.org\/10.1007\/s11060-016-2318-3","journal-title":"J Neurooncol"},{"key":"6205_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/bloodadvances.2016000927","volume":"1","author":"J Fallah","year":"2016","unstructured":"Fallah J, Qunaj L, Olszewski AJ (2016) Therapy and outcomes of primary central nervous system lymphoma in the united States: analysis of the National Cancer database. Blood Adv 1:112\u2013121. https:\/\/doi.org\/10.1182\/bloodadvances.2016000927","journal-title":"Blood Adv"},{"key":"6205_CR13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/jco.2003.09.139","volume":"21","author":"AJ Ferreri","year":"2003","unstructured":"Ferreri AJ, Blay JY, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. J Clin Oncol 21:266\u2013272. https:\/\/doi.org\/10.1200\/jco.2003.09.139","journal-title":"J Clin Oncol"},{"key":"6205_CR14","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","volume":"374","author":"AJ Ferreri","year":"2009","unstructured":"Ferreri AJ, Reni M, Foppoli M et al (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374:1512\u20131520","journal-title":"Lancet"},{"key":"6205_CR15","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/s2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E et al (2016a) Chemoimmunotherapy with methotrexate, cytarabine, Thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3:e217\u2013227. https:\/\/doi.org\/10.1016\/s2352-3026(16)00036-3","journal-title":"Lancet Haematol"},{"key":"6205_CR16","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E et al (2016b) Chemoimmunotherapy with methotrexate, cytarabine, Thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3:e217\u2013e227","journal-title":"Lancet Haematol"},{"key":"6205_CR17","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/s2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E et al (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the international extranodal lymphoma study Group-32 phase 2 trial. Lancet Haematol 4:e510\u2013e523. https:\/\/doi.org\/10.1016\/s2352-3026(17)30174-6","journal-title":"Lancet Haematol"},{"key":"6205_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","volume":"9","author":"AJM Ferreri","year":"2023","unstructured":"Ferreri AJM, Calimeri T, Cwynarski K et al (2023) Primary central nervous system lymphoma. Nat Rev Dis Primers 9:29. https:\/\/doi.org\/10.1038\/s41572-023-00439-0","journal-title":"Nat Rev Dis Primers"},{"key":"6205_CR19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1080\/13543784.2016.1208170","volume":"25","author":"S Garciaz","year":"2016","unstructured":"Garciaz S, Coso D, Schiano de Colella JM, Bouabdallah R (2016) Lenalidomide for the treatment of B-cell lymphoma. Expert Opin Investig Drugs 25:1103\u20131116. https:\/\/doi.org\/10.1080\/13543784.2016.1208170","journal-title":"Expert Opin Investig Drugs"},{"key":"6205_CR20","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"30","author":"H Ghesquieres","year":"2019","unstructured":"Ghesquieres H, Chevrier M, Laadhari M et al (2019) Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u2018proof of concept\u2019 phase II study of the French Oculo-Cerebral lymphoma (LOC) network and the lymphoma study association (LYSA)\u2020. Ann Oncol 30:621\u2013628. https:\/\/doi.org\/10.1093\/annonc\/mdz032","journal-title":"Ann Oncol"},{"key":"6205_CR21","doi-asserted-by":"publisher","first-page":"e114398","DOI":"10.1371\/journal.pone.0114398","volume":"9","author":"KZ Gill","year":"2014","unstructured":"Gill KZ, Iwamoto F, Allen A, Hoehn D, Murty VV, Alobeid B, Bhagat G (2014) MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system. PLoS ONE 9:e114398. https:\/\/doi.org\/10.1371\/journal.pone.0114398","journal-title":"PLoS ONE"},{"key":"6205_CR22","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.Cd-17-0613","volume":"7","author":"C Grommes","year":"2017","unstructured":"Grommes C, Pastore A, Palaskas N et al (2017) Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov 7:1018\u20131029. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0613","journal-title":"Cancer Discov"},{"key":"6205_CR23","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/apm.12623","volume":"124","author":"S Guo","year":"2016","unstructured":"Guo S, Bai Q, Rohr J et al (2016) Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication. Apmis 124:1054\u20131062. https:\/\/doi.org\/10.1111\/apm.12623","journal-title":"Apmis"},{"key":"6205_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/hon.2727","volume":"38","author":"S Hatzl","year":"2020","unstructured":"Hatzl S, Posch F, Deutsch A et al (2020) Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma. Hematol Oncol 38:277\u2013283. https:\/\/doi.org\/10.1002\/hon.2727","journal-title":"Hematol Oncol"},{"key":"6205_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1212\/wnl.0000000000001158","volume":"84","author":"C Houillier","year":"2015","unstructured":"Houillier C, Choquet S, Touitou V et al (2015) Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma. Neurology 84:325\u2013326. https:\/\/doi.org\/10.1212\/wnl.0000000000001158","journal-title":"Neurology"},{"key":"6205_CR26","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/jco.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"Houillier C, Taillandier L, Dureau S et al (2019) Radiotherapy or autologous Stem-Cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol 37:823\u2013833. https:\/\/doi.org\/10.1200\/jco.18.00306","journal-title":"J Clin Oncol"},{"key":"6205_CR27","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1212\/wnl.0000000000008900","volume":"94","author":"C Houillier","year":"2020","unstructured":"Houillier C, Soussain C, Ghesqui\u00e8res H et al (2020) Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology 94:e1027\u2013e1039. https:\/\/doi.org\/10.1212\/wnl.0000000000008900","journal-title":"Neurology"},{"key":"6205_CR28","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/jco.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson NA, Slack GW, Savage KJ et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3452\u20133459. https:\/\/doi.org\/10.1200\/jco.2011.41.0985","journal-title":"J Clin Oncol"},{"key":"6205_CR29","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/annonc\/mdv076","volume":"26","author":"B Kasenda","year":"2015","unstructured":"Kasenda B, Ferreri AJ, Marturano E et al (2015) First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. Ann Oncol 26:1305\u20131313. https:\/\/doi.org\/10.1093\/annonc\/mdv076","journal-title":"Ann Oncol"},{"key":"6205_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood-2016-01-650101","volume":"128","author":"B Kasenda","year":"2016","unstructured":"Kasenda B, Loeffler J, Illerhaus G, Ferreri AJ, Rubenstein J, Batchelor TT (2016) The role of whole brain radiation in primary CNS lymphoma. Blood 128:32\u201336. https:\/\/doi.org\/10.1182\/blood-2016-01-650101","journal-title":"Blood"},{"key":"6205_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrc2297","volume":"8","author":"AG Letai","year":"2008","unstructured":"Letai AG (2008) Diagnosing and exploiting Cancer\u2019s addiction to blocks in apoptosis. Nat Rev Cancer 8:121\u2013132. https:\/\/doi.org\/10.1038\/nrc2297","journal-title":"Nat Rev Cancer"},{"key":"6205_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11060-018-2940-3","volume":"140","author":"K Makino","year":"2018","unstructured":"Makino K, Nakamura H, Shinojima N, Kuroda JI, Yano S, Mikami Y, Mukasa A (2018) BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma. J Neurooncol 140:115\u2013121. https:\/\/doi.org\/10.1007\/s11060-018-2940-3","journal-title":"J Neurooncol"},{"key":"6205_CR33","doi-asserted-by":"publisher","unstructured":"Nguyen L, Papenhausen P, Shao H (2017) The role of c-MYC in B-Cell lymphomas: diagnostic and molecular aspects. Genes (Basel) 8. https:\/\/doi.org\/10.3390\/genes8040116","DOI":"10.3390\/genes8040116"},{"key":"6205_CR34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2174\/1568009616666160408145741","volume":"16","author":"JC Riches","year":"2016","unstructured":"Riches JC, Gribben JG (2016) Mechanistic and clinical aspects of Lenalidomide treatment for chronic lymphocytic leukemia. Curr Cancer Drug Targets 16:689\u2013700. https:\/\/doi.org\/10.2174\/1568009616666160408145741","journal-title":"Curr Cancer Drug Targets"},{"key":"6205_CR35","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1002\/cncr.31646","volume":"124","author":"PA Riedell","year":"2018","unstructured":"Riedell PA, Smith SM (2018) Double hit and double expressors in lymphoma: definition and treatment. Cancer 124:4622\u20134632. https:\/\/doi.org\/10.1002\/cncr.31646","journal-title":"Cancer"},{"key":"6205_CR36","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","volume":"31","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Hsi ED, Johnson JL et al (2013) Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 31:3061\u20133068","journal-title":"J Clin Oncol"},{"key":"6205_CR37","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/hon.2315","volume":"35","author":"M Salati","year":"2017","unstructured":"Salati M, Tarantino V, Maiorana A, Bettelli S, Luminari S (2017) Durable remission in a patient with leptomeningeal relapse of a MYC\/BCL6-positive double-hit DLBCL treated with Lenalidomide monotherapy. Hematol Oncol 35:861\u2013863. https:\/\/doi.org\/10.1002\/hon.2315","journal-title":"Hematol Oncol"},{"key":"6205_CR38","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1006\/bcmd.2000.0372","volume":"27","author":"CA Schmitt","year":"2001","unstructured":"Schmitt CA, Lowe SW (2001) Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. Blood Cells Mol Dis 27:206\u2013216. https:\/\/doi.org\/10.1006\/bcmd.2000.0372","journal-title":"Blood Cells Mol Dis"},{"key":"6205_CR39","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/jnen\/nlx083","volume":"76","author":"QY Shi","year":"2017","unstructured":"Shi QY, Feng X, Bao W et al (2017) MYC\/BCL2 Co-Expression is a stronger prognostic factor compared with the Cell-of-Origin classification in primary CNS DLBCL. J Neuropathol Exp Neurol 76:942\u2013948. https:\/\/doi.org\/10.1093\/jnen\/nlx083","journal-title":"J Neuropathol Exp Neurol"},{"key":"6205_CR40","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/s1470-2045(10)70229-1","volume":"11","author":"E Thiel","year":"2010","unstructured":"Thiel E, Korfel A, Martus P et al (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036\u20131047. https:\/\/doi.org\/10.1016\/s1470-2045(10)70229-1","journal-title":"Lancet Oncol"},{"key":"6205_CR41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrc2819","volume":"10","author":"J van Riggelen","year":"2010","unstructured":"van Riggelen J, Yetil A, Felsher DW (2010) MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer 10:301\u2013309. https:\/\/doi.org\/10.1038\/nrc2819","journal-title":"Nat Rev Cancer"},{"key":"6205_CR42","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1200\/jco.2010.31.3601","volume":"29","author":"KE Warren","year":"2011","unstructured":"Warren KE, Goldman S, Pollack IF et al (2011) Phase I trial of Lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: pediatric brain tumor consortium study PBTC-018. J Clin Oncol 29:324\u2013329. https:\/\/doi.org\/10.1200\/jco.2010.31.3601","journal-title":"J Clin Oncol"},{"key":"6205_CR43","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.3324\/haematol.2023.284834","volume":"109","author":"X Yuan","year":"2024","unstructured":"Yuan X, Xie Y, Xu N et al (2024) Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma. Haematologica 109:2005\u20132009. https:\/\/doi.org\/10.3324\/haematol.2023.284834","journal-title":"Haematologica"},{"key":"6205_CR44","doi-asserted-by":"publisher","first-page":"6608","DOI":"10.1182\/blood-2022-165934","volume":"140","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wang W, Li J et al (2022) Phase Ib\/II study of rituximab, Lenalidomide and methotrexate followed by Lenalidomide maintenance in patients with newly diagnosed primary CNS lymphoma: the Remla trial. Blood 140:6608\u20136609. https:\/\/doi.org\/10.1182\/blood-2022-165934","journal-title":"Blood"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06205-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06205-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06205-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T01:38:45Z","timestamp":1749865125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06205-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["6205"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06205-x","relation":{},"ISSN":["1432-1335"],"issn-type":[{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the affiliations for authors Lijie Liang and Ming Jiang.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Biomedical Research, West China Hospital of Sichuan University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"173"}}